Sequenta has introduced a sequencing-based test for minimal residual disease (MRD) for leukemia and lymphoma. The ClonoSIGHT test utilizes the company's proprietary LymphoSIGHT technology, which works by sequencing DNA signatures that are ...
Tags: Sequenta, sequencing-based test, minimal residual disease
Eastern Cooperative Oncology Group, now a part of the ECOG-ACRIN Cancer Research Group, has entered into an agreement to use Sequenta's new LymphoSIGHT sequencing method in its randomized E1411 phase II trial. LymphoSIGHT is designed for ...
Sequenta has obtained clinical laboratory improvement amendments (CLIA) certification for its new clinical test, which is based on the LymphoSIGHT method. The LymphoSIGHT platform, which utilizes a proprietary assay for the amplification ...
Tags: Sequenta, CLIA, certification, clinical test, LymphoSIGHT method
SWOG (formerly the Southwest Oncology Group) has chosen Sequenta's LymphoSIGHT platform for the measurement of minimal residual disease (MRD) in 180-patient mantle cell lymphoma clinical trial. The patients in the SWOG S1106 mantle cell ...
Tags: SWOG, Sequenta's LymphoSIGHT platform, minimal residual disease, MRD